Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2439821 (ixekizumab) dose-ranging in active Rheumatoid Arthritis
NCT00966875Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of ixekizumab in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Aug 2009; status: completed.
02
Drugs
ixekizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00966875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00966875.